Search
Trastuzumab per al tractament del càncer gàstric o d'unió gastroesofàgica metàstasic HER2+: informe d'avaluació de resultats
(2018)
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor (HER2) receptor 2, which in 2010 was approved by the European Agency of the
Medication (EMA) for the treatment of gastric cancer or ...
Tractament farmacològic de la malaltia d’Alzheimer: informe del Registre de Tractament Farmacològic de la Malaltia d’Alzheimer a l’any 2018
(2019)
Alzheimer's disease (MA) is a progressive and irreversible neurodegenerative disorder usually a slow but sustained development over time. MA is the most frequent cause of dementia (69%). Its prevalence is 5.1% and increases ...
Venetoclax en monoteràpia per al tractament de la leucèmia limfocítica crònica
(2019-02-01)
Chronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. ...
Tractament de l'artritis reumatoide activa de moderada a greu quan la resposta als FAMM ha estat inadequada: informe d'avaluació de resultats 2019
(2019)
Rheumatoid arthritis (RA) is a chronic disease Invalid autoimmune due to unknown cause, which It consists of a destructive inflammation of the joints, It can also affect other parts of the body. There are no curative ...
Axicabtagen ciloleucel i tisagenlecleucel per al tractament del limfoma B de cèl·lules grans
(2019-03-21)
Axicabtagen ciloleucel and tisagenlecleucel are two gene therapies that contain
T-lymphocytes of the patient previously manipulated so they express themselves
membrane, chimeric antigenic receptor or CAR. This receiver ...